Former AIB chief financial officer Mark Bourke, a key member of the team behind the bank’s initial public offering (IPO) ...

The lender was getting ready to list in Lisbon next month despite the unsteadiness in global markets and could be valued up ...

Portuguese lender Novo Banco SA is “well advanced” in drafting a prospectus for a possible initial public offering, which it ...

Portugal's fourth-largest lender Novo Banco plans to go ahead with an initial public offering (IPO) possibly in June or September despite market volatility caused by global trade tensions, Chief ...

Portugal's fourth-largest lender Novo Banco, which is preparing for an initial public offering (IPO), said on Tuesday its ...

Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out Penfill cartridges. This decision follows concerns about the discontinuation ...

Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker's blockbuster weight loss drug Wegovy ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while larger, federally licensed compounders have until May 22 to keep ...

A federal judge refused to allow drug compounders to keep making copycats of Novo Nordisk A/S ’s weight loss drug while a lawsuit plays out over the FDA’s decision to determine that the drug is no ...

Thirty-seven-year-old Nupur Lalvani, who has been living with Type 1 diabetes since the age of eight, was dependent on insulin pens and had of late been a regular user of Novo Nordisk’s largest ...

Abbott is the marketing partner for Novo’s insulin. Confirming the development, a Novo Nordisk spokesperson said, “In order to meet increasing patient demand and ensure a stable supply of our ...

I believe Novo's dominance in diabetes and obesity drugs may soon erode, as Eli Lilly continues to gain ground at an aggressive pace. I find Novo's 2-year delayed move into oral GLP-1s uninspiring ...